Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Gene | CTNNB1 |
Variant | P44H |
Impact List | missense |
Protein Effect | unknown |
Gene Variant Descriptions | CTNNB1 P44H does not lie within any known functional domains of the Ctnnb1 protein (UniProt.org). P44H has not been characterized in the scientific literature and therefore, its effect on Ctnnb1 protein function is unknown (PubMed, Sep 2024). |
Associated Drug Resistance | |
Category Variants Paths |
CTNNB1 mutant CTNNB1 P44H |
Transcript | NM_001098210.2 |
gDNA | chr3:g.41224643C>A |
cDNA | c.131C>A |
Protein | p.P44H |
Source Database | RefSeq |
Genome Build | GRCh38/hg38 |
Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
---|---|---|---|---|---|
NM_001098209.1 | chr3:g.41224643C>A | c.131C>A | p.P44H | RefSeq | GRCh38/hg38 |
NM_001904.4 | chr3:g.41224643C>A | c.131C>A | p.P44H | RefSeq | GRCh38/hg38 |
XM_024453357.1 | chr3:g.41224643C>A | c.131C>A | p.P44H | RefSeq | GRCh38/hg38 |
XM_047447478.1 | chr3:g.41224643C>A | c.131C>A | p.P44H | RefSeq | GRCh38/hg38 |
NM_001098210.2 | chr3:g.41224643C>A | c.131C>A | p.P44H | RefSeq | GRCh38/hg38 |
XM_047447481.1 | chr3:g.41224643C>A | c.131C>A | p.P44H | RefSeq | GRCh38/hg38 |
NM_001098210.1 | chr3:g.41224643C>A | c.131C>A | p.P44H | RefSeq | GRCh38/hg38 |
XM_006712985 | chr3:g.41224643C>A | c.131C>A | p.P44H | RefSeq | GRCh38/hg38 |
XM_006712985.1 | chr3:g.41224643C>A | c.131C>A | p.P44H | RefSeq | GRCh38/hg38 |
XM_024453356.1 | chr3:g.41224643C>A | c.131C>A | p.P44H | RefSeq | GRCh38/hg38 |
NM_001904.3 | chr3:g.41224643C>A | c.131C>A | p.P44H | RefSeq | GRCh38/hg38 |
XM_047447480.1 | chr3:g.41224643C>A | c.131C>A | p.P44H | RefSeq | GRCh38/hg38 |
NM_001098209 | chr3:g.41224643C>A | c.131C>A | p.P44H | RefSeq | GRCh38/hg38 |
NM_001098209.2 | chr3:g.41224643C>A | c.131C>A | p.P44H | RefSeq | GRCh38/hg38 |
XM_017005738 | chr3:g.41224643C>A | c.131C>A | p.P44H | RefSeq | GRCh38/hg38 |
XM_017005738.1 | chr3:g.41224643C>A | c.131C>A | p.P44H | RefSeq | GRCh38/hg38 |
XM_024453358.1 | chr3:g.41224643C>A | c.131C>A | p.P44H | RefSeq | GRCh38/hg38 |
XM_047447483.1 | chr3:g.41224643C>A | c.131C>A | p.P44H | RefSeq | GRCh38/hg38 |
XM_024453356.2 | chr3:g.41224643C>A | c.131C>A | p.P44H | RefSeq | GRCh38/hg38 |
NM_001098210 | chr3:g.41224643C>A | c.131C>A | p.P44H | RefSeq | GRCh38/hg38 |
XM_005264886 | chr3:g.41224643C>A | c.131C>A | p.P44H | RefSeq | GRCh38/hg38 |
NM_001904 | chr3:g.41224643C>A | c.131C>A | p.P44H | RefSeq | GRCh38/hg38 |
XM_006712985.2 | chr3:g.41224643C>A | c.131C>A | p.P44H | RefSeq | GRCh38/hg38 |
XM_047447477.1 | chr3:g.41224643C>A | c.131C>A | p.P44H | RefSeq | GRCh38/hg38 |
XM_017005738.2 | chr3:g.41224643C>A | c.131C>A | p.P44H | RefSeq | GRCh38/hg38 |
XM_047447479.1 | chr3:g.41224643C>A | c.131C>A | p.P44H | RefSeq | GRCh38/hg38 |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
CTNNB1 mutant | colorectal cancer | sensitive | BC21 | Preclinical | Actionable | In a preclinical study, BC21 inhibited growth and viability of a colorectal cancer cell line with a CTNNB1 mutation and increased beta-catenin expression in culture (PMID: 22224445). | 22224445 |
CTNNB1 mutant | endometrial cancer | predicted - sensitive | Cabozantinib | Case Reports/Case Series | Actionable | In a Phase II (NCI9322/PHL86) trial, Cometriq (Cabometyx, cabozantinib) treatment resulted in a response rate of 40% (4/10) and a 12-week progression-free survival rate of 70% (7/10) in patients with endometrial cancer harboring CTNNB1 mutations, with a median PFS of 7.6 months (PMID: 31992589; NCT01935934). | 31992589 |
CTNNB1 mutant | hepatocellular carcinoma | predicted - sensitive | WNTinib | Preclinical - Cell culture | Actionable | In a preclinical study, WNTinib inhibited Ezh2 phosphorylation and viability in a hepatocellular carcinoma cell line harboring a deletion of CTNNB1 exons in culture (PMID: 37537299). | 37537299 |
CTNNB1 mutant | endometrial cancer | predicted - sensitive | Temsirolimus | Phase II | Actionable | In a retrospective study of a Phase II trial, Torisel (temsirolimus) treatment resulted in an increased progression-free survival (HR 0.46) but not response rate (response difference 0.00) in advanced endometrial cancer patients harboring CTNNB1 mutations (PMID: 27016228). | 27016228 |
CTNNB1 mutant | desmoid tumor | not applicable | N/A | Guideline | Diagnostic | CTNNB1 mutations aid the diagnosis of desmoid tumor (NCCN.org). | detail... |
CTNNB1 mutant | hepatocellular carcinoma | sensitive | PMED-1 | Preclinical | Actionable | In a preclinical study, PMED-1 decreased Wnt expression and decreased proliferation of hepatocellular carcinoma cells with Ctnnb1 mutations (PMID: 24819961). | 24819961 |
CTNNB1 mutant | medulloblastoma | not applicable | N/A | Guideline | Prognostic | WNT-driven medulloblastomas, characterized by CTNNB1 or APC mutations, are associated with favorable prognosis (NCCN.org). | detail... |